Nearly all of Latin America was excluded from the deal, sparking concern the world is missing a critical opportunity to stop ...

Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...

A recent phase 3 trial found that twice-yearly injections of Lenacapavir reduce the risk of contracting HIV by 96%. | Drug ...

A new, long-acting injectable to prevent HIV infection could be a “game-changer” in ending the AIDS epidemic, if all who ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

A new HIV prevention method, Lenacapavir, administered as a twice-yearly injection, has demonstrated superior results ...

Tengrinews.kz - A revolutionary HIV drug has been created: clinical trials have shown that its twice-yearly injections are 96 ...

Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.

The twice-yearly HIV prevention shot developed by Gilead has shown impressive results in preventing infections among both men ...